Clinic Roundup

 Gilead Sciences Inc., of Foster City, Calif., said top-line Phase III results showed that elvitegravir, an integrase inhibitor in development for HIV, was noninferior to the integrase inhibitor raltegravir after two years of therapy in treatment-experienced patients.